JP2015520172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520172A5 JP2015520172A5 JP2015515116A JP2015515116A JP2015520172A5 JP 2015520172 A5 JP2015520172 A5 JP 2015520172A5 JP 2015515116 A JP2015515116 A JP 2015515116A JP 2015515116 A JP2015515116 A JP 2015515116A JP 2015520172 A5 JP2015520172 A5 JP 2015520172A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- variable region
- chain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000025171 antigen binding proteins Human genes 0.000 description 5
- 108091000831 antigen binding proteins Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654019P | 2012-05-31 | 2012-05-31 | |
| US61/654,019 | 2012-05-31 | ||
| PCT/US2013/042912 WO2014062245A2 (en) | 2012-05-31 | 2013-05-28 | Antigen binding proteins that bind dll-4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520172A JP2015520172A (ja) | 2015-07-16 |
| JP2015520172A5 true JP2015520172A5 (enExample) | 2016-07-14 |
Family
ID=49670535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515116A Pending JP2015520172A (ja) | 2012-05-31 | 2013-05-28 | Ｄｌｌ−４に結合する抗原結合蛋白質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10174107B2 (enExample) |
| EP (1) | EP2855523A4 (enExample) |
| JP (1) | JP2015520172A (enExample) |
| CN (1) | CN104603151A (enExample) |
| CA (1) | CA2874979A1 (enExample) |
| HK (1) | HK1206038A1 (enExample) |
| WO (1) | WO2014062245A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| SI3485903T1 (sl) | 2011-09-23 | 2023-02-28 | Mereo Biopharma 5, Inc. | Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe |
| WO2014062245A2 (en) | 2012-05-31 | 2014-04-24 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind dll-4 |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| CN114853891A (zh) * | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US20070244709A1 (en) * | 2006-04-17 | 2007-10-18 | Earthworks Systems, Llc | Methods of producing and recycling plastic cards |
| AR061246A1 (es) * | 2006-06-06 | 2008-08-13 | Genentech Inc | Anticuerpos anti- dill4 y metodos que los usan |
| HUE028379T2 (en) * | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CN102264763B (zh) * | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| US8623358B2 (en) * | 2009-08-29 | 2014-01-07 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
| WO2014062245A2 (en) | 2012-05-31 | 2014-04-24 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind dll-4 |
-
2013
- 2013-05-28 WO PCT/US2013/042912 patent/WO2014062245A2/en not_active Ceased
- 2013-05-28 HK HK15106562.8A patent/HK1206038A1/xx unknown
- 2013-05-28 US US13/903,793 patent/US10174107B2/en active Active
- 2013-05-28 CA CA2874979A patent/CA2874979A1/en not_active Abandoned
- 2013-05-28 EP EP13847493.7A patent/EP2855523A4/en not_active Withdrawn
- 2013-05-28 JP JP2015515116A patent/JP2015520172A/ja active Pending
- 2013-05-28 CN CN201380028998.XA patent/CN104603151A/zh active Pending
-
2019
- 2019-01-07 US US16/241,828 patent/US10717779B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7457764B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP2015519375A5 (enExample) | ||
| JP7496091B2 (ja) | 合理的に設計された新規なタンパク質組成物 | |
| ES2988145T3 (es) | Anticuerpos humanizados contra c-kit | |
| ES2654551T3 (es) | Anticuerpo contra el CSF-1R | |
| JP2021510710A5 (enExample) | ||
| JP7620807B2 (ja) | 抗ＳＩＲＰα抗体およびその適用 | |
| ES2967739T3 (es) | Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA | |
| JP7600328B2 (ja) | ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP2019511201A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| JP2018536393A (ja) | 抗ｗｔ１／ｈｌａ特異的抗体 | |
| EP2954056A1 (en) | Novel multispecific constructs | |
| KR20210099027A (ko) | 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 | |
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2019512207A5 (enExample) | ||
| KR20230141817A (ko) | 이중특이 항체 | |
| BR112019022702A2 (pt) | gama de anticorpos anti-interferon e utilizações dos mesmos. | |
| JP2025541367A (ja) | 多価および多重特異性サイトカインアンタゴニスト | |
| JP2016529213A5 (enExample) | ||
| JP2021506310A5 (enExample) | ||
| CN116710136A (zh) | Prame结合性分子 | |
| WO2023052447A2 (en) | Methods and compositions | |
| WO2022228514A1 (zh) | 抗人白血病抑制因子抗体及其用途 | |
| EA049093B1 (ru) | Гуманизированные антитела к c-kit |